Cullinan Therapeutics’ (CGEM) Buy Rating Reaffirmed at BTIG Research

Cullinan Therapeutics (NASDAQ:CGEM)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a research note issued on Friday, Benzinga reports. They presently have a $40.00 price objective on the stock. BTIG Research’s price objective suggests a potential upside of 162.55% from the company’s current price.

Other research analysts also recently issued reports about the company. TD Cowen raised Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Wedbush lifted their price target on Cullinan Therapeutics from $39.00 to $42.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. HC Wainwright lifted their price target on Cullinan Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Wednesday, July 8th. Finally, Wall Street Zen cut Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 13th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cullinan Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $33.71.

Cullinan Therapeutics Stock Performance

Shares of Cullinan Therapeutics stock traded down $0.21 during trading on Friday, hitting $15.24. 128,193 shares of the stock traded hands, compared to its average volume of 892,082. The stock has a market cap of $980.52 million, a P/E ratio of -4.93 and a beta of 0.02. Cullinan Therapeutics has a twelve month low of $5.68 and a twelve month high of $23.19. The company has a fifty day moving average price of $19.83 and a two-hundred day moving average price of $16.71.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.01). On average, equities research analysts expect that Cullinan Therapeutics will post -3.08 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Jennifer Michaelson sold 8,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total value of $172,560.00. Following the sale, the insider owned 158,844 shares of the company’s stock, valued at $3,426,265.08. The trade was a 4.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders sold 46,000 shares of company stock valued at $922,920. 8.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Cullinan Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CGEM. AlphaCentric Advisors LLC increased its holdings in Cullinan Therapeutics by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 20,135 shares of the company’s stock valued at $286,000 after purchasing an additional 1,094 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in Cullinan Therapeutics in the second quarter valued at about $25,000. ProShare Advisors LLC increased its holdings in Cullinan Therapeutics by 15.3% in the fourth quarter. ProShare Advisors LLC now owns 12,489 shares of the company’s stock valued at $129,000 after purchasing an additional 1,661 shares during the last quarter. Allworth Financial LP increased its holdings in Cullinan Therapeutics by 152.4% in the second quarter. Allworth Financial LP now owns 2,893 shares of the company’s stock valued at $53,000 after purchasing an additional 1,747 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in Cullinan Therapeutics by 160.6% in the first quarter. Royal Bank of Canada now owns 4,044 shares of the company’s stock valued at $58,000 after purchasing an additional 2,492 shares during the last quarter. Institutional investors and hedge funds own 86.31% of the company’s stock.

Cullinan Therapeutics News Summary

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $40 price target, implying substantial upside from the recent trading level. This indicates the firm believes Cullinan’s pipeline is undervalued. BTIG Research rating and price target
• Positive Sentiment: Cullinan outlined multiple fourth-quarter 2026 data catalysts, including velinotamig multi-dose data in systemic lupus erythematosus at the November ACR Convergence meeting, plus CLN-978 data in lupus, rheumatoid arthritis and Sjögren’s disease and updated CLN-049 Phase 1 data in December. Cullinan Therapeutics fourth-quarter pipeline milestones
• Neutral Sentiment: The company’s broader T-cell engager pipeline remains the main source of potential value, with clinical updates planned across three programs. The impact will depend on the quality and durability of the forthcoming data. Cullinan Therapeutics T-cell engager milestones
• Negative Sentiment: Cullinan delayed an early-stage clinical update for its arthritis therapy until December. The postponement removes a near-term catalyst and has increased investor uncertainty regarding the program’s progress. Cullinan delays arthritis therapy data
• Negative Sentiment: Although recent Phase 3 zipalertinib data for lung cancer were described as strong, investor concerns about the drug’s safety profile remain. Those concerns have overshadowed the efficacy data and contributed to the stock’s decline. CGEM losses and zipalertinib safety concerns

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.